Check Out Prime’s New Resource Guide for X-linked Hypophosphatemia!
source: pixabay.com

Check Out Prime’s New Resource Guide for X-linked Hypophosphatemia!

A new resource guide has been developed for X-linked hypophosphatemia (XLH) by Prime, a medical education firm. This project has been supported by Ultragenyx Pharmaceutical Inc. The guide provides resources…

Continue Reading Check Out Prime’s New Resource Guide for X-linked Hypophosphatemia!
The Drug Burosumab Demonstrates Long-Term Benefits for X-Linked Hypophosphatemia
source: pixabay.com

The Drug Burosumab Demonstrates Long-Term Benefits for X-Linked Hypophosphatemia

According to a story from Medscape, the drug burosumab (marketed as Crysvita) demonstrated its ability to provide long term benefits for nearly two years to patients with the rare disease…

Continue Reading The Drug Burosumab Demonstrates Long-Term Benefits for X-Linked Hypophosphatemia

Phase 3 Study Shows Burosumab is Superior than Traditional Therapies for X-Linked Hypophosphatemia (XLH)

At the 2019 annual meeting of The Endocrine Society, ENDO 2019, results from a recent study evaluating burosumab for the treatment of X-linked hypophosphatemia (XLH) were presented. This drug was…

Continue Reading Phase 3 Study Shows Burosumab is Superior than Traditional Therapies for X-Linked Hypophosphatemia (XLH)
First Treatment for X-Linked Hypophosphatemia Gains Approval in Canada
Taokinesis / Pixabay

First Treatment for X-Linked Hypophosphatemia Gains Approval in Canada

According to a story from pm360online.com, the biopharmaceutical company Ultragenyx Pharmaceutical Inc., in collaboration with Kyowa Hakko Kirin Co. Ltd, and Kyowa Kirin International PLC, recently announced that injectable burosumab…

Continue Reading First Treatment for X-Linked Hypophosphatemia Gains Approval in Canada
Drug for X-Linked Hypophosphatemia Turned Down in the UK Because of Cost
Free-Photos / Pixabay

Drug for X-Linked Hypophosphatemia Turned Down in the UK Because of Cost

According to a story from Fierce Pharma, the National Institute for Health Care and Excellence (NICE) has decided to reject the drug Crysvita for coverage on the National Health Service…

Continue Reading Drug for X-Linked Hypophosphatemia Turned Down in the UK Because of Cost
New Drug Gains Approval For Treating X-Linked Hypophosphatemia in the U.S.
source: pixabay.com

New Drug Gains Approval For Treating X-Linked Hypophosphatemia in the U.S.

According to a story from globenewswire.com, the pharmaceutical companies Ultragenyx and Kyowa Kirin recently issued an announcement that the U.S. FDA has granted approval to their new treatment Crysvita (burosumab-twza).…

Continue Reading New Drug Gains Approval For Treating X-Linked Hypophosphatemia in the U.S.
Drug Clinical Trial Reports Back Positive Results for Rare Bone Disease
Source: Pixabay

Drug Clinical Trial Reports Back Positive Results for Rare Bone Disease

Great news for the rare disease community! Ultragenyx Pharmaceuticals reported back positive results from its phase 3 study of the treatment drug burosumab in adults with X-linked hypophosphatemia (XLH). XLH…

Continue Reading Drug Clinical Trial Reports Back Positive Results for Rare Bone Disease
Close Menu